ArticleiScience2026
Epitope-driven polyfunctional divergence of SARS-CoV-2 RBD antibodies.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 antibodies targeting the receptor-binding domain (RBD) of the spike protein can potently neutralize infection and exert additional antiviral functions. Here, we characterize the functional profiles of human RBD-specific memory B cell antibodies elicited by ancestral SARS-CoV-2 infection. While SARS-CoV-2 neutralizing antibodies, mainly class 1 and 3 anti-RBD antibodies, often lose binding and neutralizing activity against Omicron variants, most non-neutralizers that bind conserved RBD epitopes remain broadly reactive. Despite their restricted cross-reactivity, neutralizing antibodies mediate Fc-effector functions including antibody-dependent cellular cytotoxicity, phagocytosis, and complement deposition. Most neutralizers also enhance binding of antibodies that target the SARS-CoV-2 spike fusion peptide via receptor-mimetic allostery. In contrast, broadly reactive non-neutralizers fail to trigger phagocytic or allosteric effects. Thus, viral escape primarily affects neutralizing, polyfunctional antibodies, whereas cross-reactive non-neutralizing antibodies, which exert limited antiviral effects, may apply minimal immune pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.